title: Treatment of metachronous and simultaneous liver metastases of pancreatic cancer.
abstract: OBJECTIVE
  Patients were analyzed who underwent treatment of liver metastases from pancreatic cancer.
  
  
  METHODS
  Selection criteria were the possibility of R0 resection of the primary and/or the liver metastases, no other sites of metastases, and the presentation of liver metastases. A comparison of treatment by surgery versus chemotherapy regarding overall survival and disease-free interval was performed.
  
  
  RESULTS
  Between 1996 and 2008, a total number of 23 patients were retrospectively identified from a prospective database of 193 cases of pancreatic cancer. In 14 cases, liver metastases were found simultaneously, and in 9 cases metachronously, fulfilling the abovementioned selection criteria. Of these, 13 patients underwent surgery and 10 were treated by gemcitabine. There were no differences in survival in patients with synchronous liver metastases of pancreatic cancer treated by resection of the primary combined with partial hepatectomy versus treatment by gemcitabine (8 vs. 11 months). In patients with metachronous liver metastases, the median survival was increased after liver resection compared to patients who were treated with gemcitabine (31 vs. 11 months).
  
  
  CONCLUSIONS
  Simultaneous resection of pancreatic cancer and liver metastases cannot be recommended. Resection of metachronous liver metastases of pancreatic cancer seems to improve survival in highly selected patients.
authors.affiliation: Department of Cardiothoracic and Vascular Surgery, Johannes Gutenberg University Hospital, Mainz, Germany. Duenschede @ htg.klinik.uni-mainz.de
authors.forename: F
authors.initials: F
authors.lastname: Dünschede
authors.forename: L
authors.initials: L
authors.lastname: Will
authors.forename: C
authors.initials: C
authors.lastname: von Langsdorf
authors.forename: M
authors.initials: M
authors.lastname: Möhler
authors.forename: P R
authors.initials: PR
authors.lastname: Galle
authors.forename: G
authors.initials: G
authors.lastname: Otto
authors.forename: C F
authors.initials: CF
authors.lastname: Vahl
authors.forename: T
authors.initials: T
authors.lastname: Junginger
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006498:Hepatectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012189:Retrospective Studies; D013997:Time Factors; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine